TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07054684: Study of BHV-1400 in IgA Nephropathy

Sponsor: Biohaven Therapeutics Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,241,680

Rescue Site Savings

+$812,736

Unlock Full NCT07054684 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07054684 Rescue Dossier →